Earnings Call · Q1 FY2026·2026-05-06

Q1 26EPS +100.00%*·Rev n/aQ4 25EPS -100.00%*·Rev n/aQ3 25EPS +64.86%·Rev n/aQ2 25EPS +74.14%·Rev n/a⚠ consensus missing

Sarepta Therapeutics, Inc. SRPT

Tamara Thornton — Director of Investor Relations

Douglas Ingram — Chief Executive Officer

Louise Rodino-Klapac — President, R&D and Tech Ops

Patrick Moss — Chief Commercial Officer

Ryan Wong — Chief Financial Officer

+5.7%1d on move date+4.3% vs SPY3d−8.4%5d−12.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SRPT calls or request research access.

More SRPT calls Browse calls Request research access